Absci to host kol seminar on abs-201 androgenetic alopecia program on december 11, 2025; announces accelerated initiation of phase 1/2a trial

Webinar on december 11 to feature leading kols in dermatology and hair loss alongside absci leadership phase 1/2a trial now expected to begin in december 2025, ahead of prior guidance vancouver, wash. and new york, oct. 15, 2025 (globe newswire) -- absci (nasdaq: absi), a clinical-stage biotech company advancing breakthrough therapeutics with generative ai, today announced the company will host a virtual seminar on december 11, 2025 at 10:00am et focused on the company's abs-201 (anti-prlr) program for androgenetic alopecia.
ABSI Ratings Summary
ABSI Quant Ranking